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ABSTRACT 
Background and aims: Globally, cardiovascular disease (CVD) is the major cause of death among patients 
with type 2 diabetes mellitus (T2DM). Improved control of LDL cholesterol with lipid-lowering medications 
and patients’ adherence to such medications have been shown associate with lower risk of CV events and 
mortality among T2DM patients. The impact of healthcare providers’ adherence to guidelines regarding 
prescription for lipid-lowering medications is unclear. This thesis aimed to assess and compare i) patients’ 
adherence to lipid-lowering medications, ii) healthcare providers’ adherence to lipid-lowering prescription 
guidelines, and iii) risk of CV events and mortality in relation to patients’ adherence to lipid-lowering 
medication and healthcare providers’ guideline adherence among patients with T2DM. 
Patients and methods: This thesis is based on four observational studies where individualized data were 
linked between Swedish National Registers. All studies included data about patients with T2DM of at least 
18 years of age. To assess patients’ adherence, our studies used information about new users of lipid-
lowering medications from pharmacy claims data in the Swedish Prescribed Drug Register. Using data from 
the Swedish National Diabetes Register, guideline adherence was assessed for healthcare providers who 
treated patients with T2DM and LDL cholesterol above the recommended target values. We used 
information about cause of death and completed admissions of in and out-patients care to analyze risk of 
CV events and mortality, adjusted for sex, age, socioeconomic status, and concurrent medications as well as 
health-related and clinical characteristics.  
Results: On average, patients’ adherence to lipid-lowering medications was higher among secondary 
prevention patients, smokers and those with concurrent cardioprotective medications, compared to lower 
adherence among patients born outside of Sweden. Healthcare providers’ adherence to lipid-lowering 
prescription guidelines was higher among patients attributed to secondary prevention and the odds of 
receiving a prescription associated with patients’ individual risk of CV events. Adjusted for potential 
confounders, risk of CV events was higher among patients with less than complete adherence to lipid-
lowering medications and that risk gradually increased as patient adherence declined, independent of 
prevention group. Healthcare providers’ adherence to guidelines had little or no impact on patients’ risk of 
CV events and mortality.  
Conclusions: Patients’ adherence to lipid-lowering medications among patients with T2DM had greater 
impact on risk of CV events and mortality compared to healthcare providers’ adherence to prescription 
guidelines for such medications. This thesis emphasizes the value of individualized diabetes care among 
T2DM patients. 
Keywords: medication adherence, refill adherence, medication persistence, pharmacoepidemiology, lipid-
lowering medications, type 2 diabetes mellitus, cardiovascular disease, all-cause mortality, cardiovascular 
mortality, guideline adherence 
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
Hjärt-kärlsjukdomar är den främsta dödsorsaken hos patienter med typ 2-
diabetes. Förbättrad kontroll av patientens kolesterolvärden med hjälp av 
kolesterolsänkande läkemedel och patientens följsamhet till denna 
behandlingen har visats reducera risken för så väl hjärtinfarkt och stroke som 
död. Huruvida risken för hjärt-kärlhändelser och död påverkas av den 
behandlade vårdgivarens följsamhet till de nationella riktlinjerna vad gäller 
förskrivning av kolesterolsänkande läkemedel är oklart. 
Det övergripande syftet med denna avhandling var att undersöka om, och hur, 
risken för hjärt-kärlsjukdom och död påverkas av patientens följsamhet till 
kolesterolsänkande läkemedel och den behandlande vårdgivarens följsamhet 
till förskrivning av sådana läkemedel hos patienter med typ 2-diabetes.  
Avhandlingen baseras på observationsstudier där data från vuxna patienter 
med typ 2-diabetes har länkats mellan flera nationella register. Patienter med 
tidigare hjärt-kärlsjukdom ansågs använda kolesterolsänkande läkemedel för 
sekundärprevention, resterande patienter ansågs använda primärprevention. 
Patientens följsamhet beräknades med hjälp av information om uthämtade 
läkemedel från Läkemedelsregistret. Vårdgivarens följsamhet representerade 
förskrivningen av kolesterolsterolsänkande läkemedel till patienter med typ 2-
diabetes och högt LDL-kolesterol. 
Vi fann att patienter med kolesterolsänkande sekundärprevention, rökare och 
de med uttag av blodtryckssänkande och blodförtunnande läkemedel hade en 
högre följsamhet till sin kolesterolsänkande behandling. Lägre följsamhet 
observerades främst bland patienter födda utanför Sverige. Vårdgivarnas 
följsamhet till kolesterolsänkande riktlinjer var även den högre bland patienter 
med sekundärprevention och vid samtidig förskrivning av diabetesmediciner 
samt blodtryckssänkande och blodförtunnande läkemedel. Vi fann även att 
risken för hjärt-kärlshändelser ökade med avtagande patientföljsamhet i båda 
preventionsgrupperna. Vårdgivarnas följsamhet påverkade risken för 
kardiovaskulära händelser och död i låg utsträckning.  
Denna avhandling belyser värdet av individualiserad diabetesvård för patienter 
med typ 2-diabetes. 
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 ABBREVIATIONS 
  
ATC Anatomical Therapeutic Chemical Classification System 
BMI Body Mass Index 
CABG Coronary Artery Bypass Grafting 
CI Confidence interval 
CMA Continuous measure of medication acquisition  
CMG Continuous measure of medication gaps 
CV Cardiovascular 
CVD Cardiovascular disease 
DM Diabetes mellitus 
eGFR Estimated glomerular filtration rate 
HbA1c Glycated hemoglobin 
HDL-C High-density lipoprotein cholesterol 
HR Hazard ratio 
ICD International Classification of Diseases 
ICD-O International Classification of Diseases for Oncology 
IQR Inter quartile range 
ISCO International System for Classification of Occupations 
KM Kaplan-Meier (survival curves) 
LDL-C Low-density lipoprotein cholesterol 
LISA Longitudinal Integration Database for Health Insurance and Labour Market Studies 
MEMS Medication Event Monitoring Systems 
MICE Multivariate Imputations of Chained Equations 
MPR Medication possession ratio 
NDR Swedish National Diabetes Register 
OR Odds ratio 
PA Physical activity 
PCI Percutaneous Coronary Intervention 
PDC Proportion of days covered 
PIN Personal identity number 
SD Standard deviation 
SPDR Swedish Prescribed Drug Register 
T2DM Type 2 diabetes mellitus 
WHO World Health Organization 
 
  
 DEFINITIONS IN SHORT 
 
Adherence The extent to which a person acts in accordance to agreed 
recommendations 
 
 
Anatomical Therapeutic 
Chemical Classification 
System 
System used for classification of active substances according to the 
organ or system on which they act and their therapeutic, 
pharmacological and chemical properties  
 
 
Cardioprotective 
medications 
Medications used for prevention of CVD (e.g., antihypertensives, 
anticoagulants, lipid-lowering medications, etc.) 
 
 
Guideline adherence Healthcare providers’ adherence to recommended clinical practice 
guidelines 
 
 
Multidose dispensed 
medications 
Sachets in which medications are dispensed according to the intended 
time of administration  
 
 
Over-the-counter 
medications  
Medications sold without prescription 
 
 
 
Pill-count medication 
adherence 
 
Medication adherence measured by counting number of pills and 
compare with prescription instructions 
 
 
Refill adherence Measuring patient adherence using data from pharmacy claims 
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1 INTRODUCTION 
1.1 Adherence 
1.1.1 Medication adherence 
The extent to which a patient follows agreed recommendations from a 
healthcare provider is referred to as medication adherence [1]. Within 
healthcare, the importance of bilateral communication between healthcare 
providers and patients is emphasized as they seek the most appropriate 
treatment. Adherence should be differentiated from compliance, which refer to 
how well a patient follows recommendations from a healthcare provider, and 
suggests a one-sided communication, wherein the healthcare provider decides 
on a treatment and the patients is assumed to comply. In this context, 
noncompliance may interpreted as a patient’s incompetence to follow 
instructions [2]. Adherence implies that a patient is free to decide whether to 
adhere to the treatment. 
 
We currently lack uniformity standards to define medication adherence, 
although several have been proposed [3-5]. In 2009, the European Society for 
Patient Adherence, Compliance and Persistence suggested that medication 
adherence includes initiation, implementation, discontinuation, and 
persistence to treatment [4]. In this thesis, initiation refers to patients’ action 
of taking their first daily dose of a filled prescription. Implementation represent 
the proportion of time that patients have medications available during the study 
period. Discontinuation occurs when patients prematurely stop taking their 
medications, and persistence refers to the time between initiation and 
discontinuation of treatment. Patients who never fill their initial prescription 
are considered primary nonadherent to treatment. 
1.1.2 Assessing medication adherence 
The most accurate measure of medication adherence involves patients’ actual 
behavior (e.g., ingestion of medications). Because studying such ingestion is 
difficult, several proxies for direct and indirect measures of patient adherence 
have been proposed [6]. Measuring substance concentrations in bodily fluids 
is a direct assessment of medication use. However, this time-consuming 
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method may overestimate medication adherence if nonadherent patients 
initiate medications immediately before measurement and then revert to 
nonadherence. 
 
Indirect measures of adherence include self-reporting (e.g., questionnaires, 
interviews, diaries, etc.); electronic monitoring using medication event 
monitoring systems (MEMS); and use of register data (e.g., prescription 
databases, pharmacy claims databases, etc.) [7].  Self-reporting is susceptible 
to recall bias, especially if previous medication use occurred several years ago. 
In MEMS, the bottle cap records each time the medication container is opened 
and closed, but it does not measure whether the patient actually removes pills 
from the bottle. 
 
Register data from prescription or pharmacy-claims databases measure patient 
adherence retrospectively, without the influence of recall bias. However, data 
on issued prescriptions tend to overestimate adherence because patients do not 
always fill their prescriptions. Measuring patient adherence using pharmacy-
claims data (i.e., refill adherence) correlates to other adherence measures in 
varying degrees; pill count medication adherence showing highest 
concordance [6, 8-11]. However, refill adherence cannot assure patients’ 
ingestion of the medications. 
 
Several methods can assess the different aspects of medication use, such as 
days with or without medications available as well as time of continuous use 
[6, 8]. The medication possession ratio (MPR), proportion of days covered 
(PDC), and continuous measure of medication acquisition (CMA) share the 
ability to measure medication availability [8]. MPR represents the ratio 
between number of days with medication available and the number of 
observation days. PDC measures the proportion of days with medication 
available during the observation period and truncates the total supply to 100% 
to deal with medication oversupplies. CMA measures adherence during a 
cumulative period of time. These measures provide similar estimates when 
CMA and MPR do not permit adherence above 100%. 
 
The continuous measure of medication gaps (CMG) identifies total number of 
treatment gaps during a study period [8]. The maximum gap method identifies 
smaller gaps between filled prescriptions and provide information about 
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insufficient medication supplies among patients with less than complete refill 
adherence [12-14]. Larger gaps are often used to define premature 
discontinuation of treatment and help to identify patients’ persistence to 
medications [9, 15]. 
1.1.3 Guideline adherence 
Guideline adherence refers to the extent to which healthcare providers adhere 
to recommended clinical practice guidelines (e.g., interventions and 
prescription of medications). Such guidelines are based on current research and 
experience with the aim of reducing practice variations, improve patient 
outcomes, and provide equal care. Despite efforts in implementing treatment 
guidelines, the impact on clinical practice varies considerably [16, 17]. In 
Sweden, the National Board of Health and Welfare provides guidelines on a 
national level [18]. In addition, first and second-line medication treatments are 
decided by each county council. 
 
Healthcare providers’ adherence to guidelines can be measured using data 
from prescription or pharmacy claims databases as well as using physicians 
survey data or medical records [15, 19-22]. Although treatment guidelines are 
intended to support and provide guidance to those who make decisions about 
treatment, the complexity of guidelines make it difficult to standardize 
measures of guideline adherence. 
1.1.4 Factors influencing adherence 
Many factors influence adherence behaviors among healthcare providers and 
patients. Sometimes the behavior of one party will affect the adherence in the 
other or vice versa [23, 24]. For example, a patient’s attitude toward following 
the recommended treatment regimen will affect a healthcare provider’s 
prescription for treatment. Furthermore, a healthcare provider’s attitude toward 
the recommended treatment regimen may affect a patient’s willingness to 
adhere to the prescribed treatment [23]. Moreover, healthcare providers who 
delay the prescription process may affect patients’ awareness of recommended 
treatment or leave patients without available medications and thus 
involuntarily nonadherent. 
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Cost-related nonadherence may occur when insurance does not cover the 
medications and a patient’s co-payment negatively affects his or her adherence 
pattern [25-28]. Patients in Sweden pay a maximum cost during a 12-month 
period for prescribed medications covered by the Swedish Pharmaceutical 
Benefits Scheme [29]. The maximum cost has increased from 1800 Swedish 
krona in 1999 to 2250 Swedish krona in 2018 (1 €≈10 Swedish krona). 
1.1.5 Consequences of nonadherence 
There is always a reason for nonadherence, whether intended or not. 
Healthcare providers should always consider that failed therapy may be a 
consequence of poor adherence. Nonadherence among healthcare providers 
and patients may lead to negative effects on patients’ health. For example, low 
medication adherence to diabetes medications and cardioprotective 
medications (e.g., antihypertensives, lipid-lowering medication, 
anticoagulants) has been found associate with higher risk of hospitalization 
[30-33]. Furthermore, healthcare provider nonadherence implies that a 
treatment does not correspond with recommended guidelines or that patients 
do not receive the appropriate treatment, possibly exposing them to 
unnecessary risk of morbidities. 
 
On one hand, nonadherence among patients and healthcare providers may 
result in insufficient treatment. On the other hand, nonadherence may be 
legitimate in case of premature discontinuation resulting from adverse drug 
reactions. However, dosage adjustments or changing medications may 
eliminate any adverse drug reaction, whereas lack of adjustment or changes 
may result in serious morbidity or death. 
1.2 Type 2 diabetes mellitus 
1.2.1 Prevalence and incidence 
The global prevalence of diabetes mellitus (DM) is increasing, almost doubling 
since the 1980s [34]. In 2017, 8.8% of the world population lived with DM; by 
2045, that prevalence will increase with 48% [35]. Type 2 diabetes mellitus 
(T2DM) accounts for around 90% of all individuals living with DM. Although 
most individuals with T2DM live in low and middle-income countries, the 
occurrence of T2DM is more prevalent in high-income countries [35]. 
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In Sweden, the prevalence of DM is estimated at approximately 5%, which is 
reportedly lower compared to most other countries in Europe or the Americas 
[36]. This means around 450,000 individuals live with T2DM in Sweden [34]. 
Between 2007 and 2013, the incidence of DM in Sweden remained stable at 
4.4 per 1,000; higher incidence was observed among men compared to women 
[37]. 
1.2.2 Pathophysiology 
T2DM is a chronic and multifactorial disease that arises from pancreatic beta 
cell failure and decreasing insulin sensitivity in hepatic, skeletal and adipose 
tissues [38]. Initially, beta cell production of insulin increases to compensate 
for the decreased insulin sensitivity and to maintain stable blood glucose 
levels. The progression of beta cell failure eventually results in hyperglycemia 
and T2DM.  
 
At the onset of T2DM, more than 80% of beta cell function has been lost. 
Development of T2DM derives from genetic and environmental factors (e.g., 
obesity and physical inactivity, especially in individuals with genetic 
susceptibility). Because T2DM may take years to develop, many individuals 
have T2DM without knowing it. 
1.2.3 Complications and risk factors 
Individuals with T2DM have an increased risk of developing microvascular 
and macrovascular complications [39-41]. Microvascular complications arise 
from lesions in smaller vessels, especially the eyes, kidneys and nerves. 
Macrovascular complications result from lesions or erosion in larger vessels 
and include coronary heart disease, stroke, and peripheral vascular disease. 
 
Atherosclerotic plaque erosion is the major underlying cause of cardiovascular 
disease (CVD). In T2DM, the atherosclerotic process is enhanced due to 
factors related to hyperglycemia and insulin resistance, and risk of CVD and 
mortality is higher already in patients with prediabetes (i.e., impaired fasting 
glucose or impaired glucose tolerance) [42, 43]. Although mortality rates have 
declined among Swedish T2DM patients, the risk is still higher compared to 
individuals without DM, and CVD remains the main cause of death [44]. 
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1.2.4 Treatment approach 
In 1996, Sweden established its first guidelines for diabetes care to provide 
equivalent and knowledge-based healthcare to adult patients with DM [45]. 
Guidelines are updated when new evidence emerges, and as new treatment 
regimens have become available. 
 
Management of T2DM includes intensive glycemic control, along with 
treatment of comorbidities and complications to combat the increased risk of 
CVD. Improved control of low-density lipoprotein cholesterol (LDL-C) with 
lipid-lowering medications have been shown associate with reduced risk of 
CVD and mortality in patients with T2DM [46-49]. 
 
During the time period of this thesis, Swedish national treatment guidelines for 
diabetes care recommended prescription for lipid-lowering medications for all 
patients with T2DM and LDL-C ≥2.5 mmol/l [50]. For T2DM patients with 
established CVD, the European Society of Cardiology, International Diabetes 
Federation and the American Diabetes Association recommended lipid-
lowering medications to reduce LDL-C below 1.8 mmol/l [51-53]. 
1.3 Lipid-lowering medications 
Lipid-lowering medications help to control elevated lipid levels in patients 
with dyslipidemia, and includes statins, fibrates, bile acid sequestrants, 
nicotinic acid and derivatives, and other lipid-modifying agents [54]. Statins 
are the recommended first-line treatment for CVD prevention in the general 
population and among T2DM patients worldwide. Although statins accounted 
for more than 95% of all filled prescriptions for lipid-lowering medications in 
Sweden during the overall study period of this thesis (2006–2016) [55], we did 
not study statins exclusively. Hence, the term lipid-lowering medications will 
be used throughout this thesis. 
1.3.1 Efficacy and effectiveness 
Efficacy refers to the medications capacity to produce an effect, and 
effectiveness consider the effect of real-world use. Reduction in risk of 
ischemic heart disease occurs within the first two years after lowering 
cholesterol; full reduction is achieved within five years [56]. Lowering LDL-
C (and total cholesterol) by 0.6 mmol/l has been shown associate with age-
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related risk reduction of ischemic heart disease, from 50% reduction at age 40 
years to 20% reduction at age 70 years. Lipid-lowering medication use can 
reduce serum cholesterol by 1.2 mmol/l, and have been shown to effectively 
reduce the incidence of major coronary events, coronary revascularization, and 
stroke in randomized controlled studies [57-61] and in clinical practice among 
patients with T2DM [46-49]. 
1.3.2 Adherence to lipid-lowering medications and cardiovascular 
disease – what is already known? 
Previous studies have shown healthcare providers’ adherence to lipid-lowering 
medication guidelines as varying in the general population as well as among 
patients with DM [21, 22, 62-66]. Moreover, patients with T2DM, concurrent 
prescription for other cardioprotective medication or attributed to secondary 
prevention were more likely to receive a prescription for lipid-lowering 
medications.  
 
Several studies show patients with high refill adherence and long persistence 
to lipid-lowering medications to associate with lower risk of major coronary 
events, stroke, and mortality both in primary and secondary prevention in the 
general population as well as among patients with DM and T2DM [32, 67-77]. 
However, these studies often dichotomously categorize patients as adherent 
according to a cut-off, most commonly 80% [12, 67, 70], meaning patients 
with refill adherence above 80% are considered adherent to treatment; all other 
patients are defined as nonadherent. Consequently, such studies provide no 
further information about the risk of CVD and mortality among more than 
these two levels of refill adherence. 
 
Little is known about the impact of healthcare providers’ adherence to lipid-
lowering prescription guidelines and patients’ refill adherence to lipid-
lowering medication in regard to risk of CVD and mortality among patients 
with T2DM. 
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2 AIM 
 
The overall aim of this thesis was to analyze the risk of CV events and 
mortality in relation to patients’ refill adherence and healthcare provider’ 
guideline adherence to lipid-lowering medications among patients with 
T2DM. Specifically, 
 
• Study I aimed to assess and compare patients’ refill adherence and 
persistence to lipid-lowering medications in T2DM patients by 
prevention group. 
 
• Study II aimed to analyze the association between patients’ refill 
adherence and persistence to lipid-lowering medications and risk 
of CV events and mortality in T2DM patients. 
 
• Study III aimed to assess healthcare providers’ adherence to 
guidelines regarding prescription for lipid-lowering medications 
in patients with T2DM and LDL-C above recommended target 
values. 
 
• Study IV aimed to analyze the association between patients’ refill 
adherence, healthcare providers’ guideline adherence to lipid-
lowering medications, and the subsequent risk of CV events and 
mortality in T2DM patients. 
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3 METHODS 
3.1 Study design and setting 
This thesis consists of four observational studies that linked individualized data 
between several Swedish national registers (Table 1). Sweden offers a unique 
opportunity for register studies because of the comprehensive databases of 
healthcare-related and socioeconomic data administered and validated by the 
Swedish National Board of Health and Welfare as well as Statistics Sweden. 
Linkage between registers is possible through the unique personal identity 
number (PIN) that since 1947 has been assigned at the time of birth or 
immigration [78]. PINs are assigned to individuals who intend to stay in 
Sweden for at least one year. Nonpermanent residents receive coordination 
numbers, similar to the PIN, which can be used for medical care. However, 
nonpermanent residents are not registered in national health registers and thus 
not included in national register studies. 
3.2 Data sources 
Using the unique PINs of individuals, we linked data between the 
• Swedish National Diabetes Register (NDR), 
• Swedish Prescribed Drug Register (SPDR), 
• National Patient Register, 
• Cause of Death Register, 
• Swedish Cancer Registry, and 
• Longitudinal Integration Database for Health Insurance and 
Labour Market Studies (LISA). 
Swedish law requires healthcare providers to submit data to the National Board 
of Health and Welfare [79], which administer and validates the SPDR, the 
National Patient Register, the Cause of Death Register, and the Swedish 
Cancer Registry. Statistics Sweden administers the LISA database, which 
consist of compiled data from different registers. 
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3.2.1 Swedish National Diabetes Register 
Launched in 1996 by the Swedish Society for Diabetology, the NDR is a 
national register that serves as a tool for systemically improving the quality of 
diabetes care [80]. It contains individualized data on patients’ clinical 
characteristics, the presence of complications, and results from laboratory 
analyses. Although reporting to the NDR is optional, healthcare providers 
continuously share patient data with the NDR by electronically transferring 
medical records or visiting the NDR webpage. Estimates suggest that as of 
today, 100% of specialized care clinics and 95% of primary care clinics report 
to the NDR. 
Table 1. Methodological Summary 
 Study 
 I II III IV 
Data sources     
Swedish National Diabetes Register     
Swedish Prescribed Drug Register     
National Patient Register     
Cause of Death Register     
LISA     
Swedish Cancer Registry     
Exposure     
Cardiovascular disease     
Refill adherence     
Persistence     
LDL cholesterol     
Guideline adherence     
Outcome     
Refill adherence     
Persistence     
Guideline adherence     
Cardiovascular event     
Mortality     
Statistical analyses     
Logistic regression     
Multivariate linear regression     
Cox proportional hazard regression     
Survival analysis     
Multiple imputations     
Mixed-effect model regression     
LDL, low-density lipoprotein; LISA, longitudinal integration Database for Health 
Insurance and Labour Market Studies. 
 13 
 
All patients included in the register, have been informed about the NDR and 
understand that they will be registered. If a patient does not consent, data from 
his or her medical records will not be reported to the NDR. In addition, a 
patient can request withdrawal from the register at a later date, after which his 
or her data is removed from the NDR. In 2017, estimates suggest that 96.5% 
of all Swedish DM patients are registered in the NDR [81]. Comparison 
between the NDR and the SPDR shows 93% conformity regarding T2DM 
patients treated with medications for diabetes. 
3.2.2 Swedish Prescribed Drug Register 
Established in July 2005 and administered by the National Corporation of 
Swedish Pharmacies, data from the SPDR is transferred to the National Board 
of Health and Welfare, which is responsible for the register [82]. 
 
The SPDR contains data on all prescriptions filled at Swedish pharmacies and 
includes variables representing patient characteristics (e.g., sex, age, place of 
residency), prescriber characteristics (e.g., profession, specialty, type of care), 
and dispensed item (date of dispensing, formula, package size, dosage 
instructions, etc.). All medications are classified according to the Anatomical 
Therapeutic Chemical (ATC) classification system [54]. The SPDR does not 
include data about over-the-counter medications or medications distributed at 
hospitals. 
3.2.3 National Patient Register 
The National Patient Register was established in 1964 and became nationwide 
in 1987 [83]. Since 2001, the register has covered both public and private 
healthcare providers. However, the register does not contain data from primary 
care clinics. The register contains information about all completed admissions 
from hospital-based care and specialized outpatient care. Diagnoses are 
classified according to the International Classification of Diseases (ICD) [84], 
interventions according to the Swedish classification of healthcare 
interventions (Swedish: Klassifikation av vårdåtgärder) [85], and surgical 
procedures according to the Swedish classification of surgical procedures 
(Swedish: Klassifikation av kirurgiska åtgärder) [86]. Since 2015, data is 
delivered to the National Board of Health and Welfare once per month. 
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3.2.4 Cause of Death Register 
Aiming to follow the development of mortality, Sweden has recorded cause of 
death since 1961 [87]. Deaths are classified according to the ICD [84]. Until 
2011, the Cause of Death Register only included individuals registered as 
residents in Sweden, independent of place of death. Since 2012, the register 
has included all deaths occurring in Sweden, independent of the deceased’s 
country of residence. 
3.2.5 Cancer Registry 
Established in 1958, the Swedish Cancer Registry contains all primary tumors 
as defined by the International Classification for Diseases for Oncology (ICD-
O) [88]. The register aims to identify the occurrence of cancer over time. 
3.2.6 Longitudinal integration database for health insurance and labour 
market studies 
Managed by Statistics Sweden, the LISA database, provides individualized 
data from several different Swedish registers (e.g., the total population register, 
income and taxation register, etc.) [89]. Data included represent demography, 
education, employment status, income, and social insurance as well as 
information about sickness and parental leaves. 
3.3 Study population and period 
Patients aged at least 18 years and registered with T2DM in the NDR were 
eligible for inclusion in all four studies in this thesis. To identify T2DM 
patients, Study I, Study II, and Study III used the epidemiological definition of 
T2DM and Study IV used the clinical diagnosis. 
 
The epidemiological definition of T2DM has been used in several studies from 
the NDR, and includes patients who receive treatment with diet and/or glucose-
lowering medications other than insulin, or who experienced the onset of 
diabetes at age ≥40 years and received insulin and/or other glucose-lowering 
medications [90-92]. The clinical diagnosis of T2DM is based on the criteria 
of the World Health Organization (WHO) (i.e., fasting glucose of ≥7 mmol/l 
or 2-hour plasma glucose ≥11 mmol/l) [93]. The epidemiological and the 
clinical definitions of T2DM are highly concordant. 
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3.3.1 Study I 
Study I included data about patients who filled at least one prescription for 
lipid-lowering medications between January 1, 2007 and December 31, 2010. 
We excluded patients who filled prescriptions for extemporaneous 
preparations, bile acid sequestrants, or a combination of lipid-lowering 
substances and/or strengths, as well as those who received noninterpretable 
dosage instructions during the study period. The methods section of Paper I 
defines combination therapy. The index date is the dispensing date of the first 
filled prescription. We followed patients from the date index date until the first 
filled prescription for multidose dispensed medications, migration, death, or 
three years after the index date. 
3.3.2 Study II 
Study II included data about patients who filled at least one prescription for 
lipid-lowering medications between January 1, 2007 and December 31, 2010. 
We measured refill adherence during an 18-month exposure period, beginning 
at the index date. We excluded patients who filled a prescription for bile acid 
sequestrants, extemporaneous preparations, multidose dispensed medications, 
or a combination of lipid-lowering substances/strengths during the exposure 
period, as well as those with noninterpretable dosage instructions at index. 
Exclusion also applied to patients who migrated, experienced a CV event, or 
died. For outcome measures, patients were followed from the first day after the 
exposure period until migration, CV event, death, or December 31, 2013. 
3.3.3 Study III 
Between January 1, 2007 and December 31, 2014, all data about T2DM 
patients were eligible for inclusion. Entries were included if they contained 
available information about LDL-C, prescription for lipid-lowering 
medications, and CVD. Our final analysis included entries with LDL-C above 
recommended target values (³2.5 mmol/l for primary prevention and ³1.8 
mmol/l for secondary prevention). 
3.3.4 Study IV 
Study IV included data about patients who filled at least one prescription for 
lipid-lowering medications (bile acid sequestrants not included) between 
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July 1, 2006 and December 31, 2012. Patients were excluded if they filled 
prescriptions for lipid-lowering extemporaneous preparations or a combination 
of lipid-lowering substances/strengths. We also excluded patients who 
received noninterpretable dosage instructions for the first filled prescription for 
lipid-lowering medications. 
 
We followed patients from the first day after their first filled prescription 
ceased (baseline date) until the first filled prescription for multidose dispensed 
medications, migration, CV event, death, or December 31, 2016. The study 
period was divided into intervals of 122 days through 2014, followed by 
intervals of 365 days through 2016. 
3.4 Exposures 
3.4.1 Cardiovascular disease 
Because Studies I–IV considered CVD as an exposure, we separated data about 
patients who had previously experienced CVD into a group for lipid-lowering 
secondary prevention. We assigned all other data (i.e. patients with no previous 
history of CVD) to lipid-lowering primary prevention. Although the definition 
of CVD encompassed diagnosed unstable angina pectoris, myocardial 
infarction, ischemic heart disease, and stroke as well as surgical procedures for 
percutaneous coronary intervention (PCI) and coronary artery bypass grafting 
(CABG), further definition differed in individual studies. A wider definition of 
CVD in Study I included heart failure, atrial fibrillation, and peripheral artery 
disease as well as surgical procedures (e.g., amputation). For ICD and surgical 
procedure codes, see Table 1, Paper I; Table 1, Paper II; and Table S1, Paper 
IV. 
3.4.2 LDL cholesterol 
Study III considered LDL-C as an exposure and data was collected from the 
NDR. We determined healthcare providers’ adherence to guidelines regarding 
lipid-lowering medications among patients with LDL-C values above the 
recommended target levels (i.e., 2.5 mmol/l in patients without established 
CVD and 1.8 mmol/l in patients with established CVD) [50, 94]. 
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We assessed refill adherence using the medication possession ratio (MPR), 
which represented the percentage of days with medications available during 
the study period. We determined MPR by dividing the number of days with 
medications available by the total number of observations days. Because we 
adjusted for overlapping supplies, MPR could not exceed 100%. 
 
Nonadherent patients were identified using the maximum gap method, which 
identifies smaller gaps between filled prescriptions and provide information 
about insufficient medication supplies. We considered gaps of at least 45 days, 
which corresponds to 50% of an average filled supply of lipid-lowering 
medications in the Swedish setting, between filled supplies as nonadherence to 
treatment. 
 
Premature discontinuation of treatment was defined as a gap of at least 180 
days (corresponds to an average of two filled supplies of lipid-lowering 
medications in the Swedish setting) between two filled supplies of lipid-
lowering medications. Persistence to treatment was measured from the index 
date until the first occurring discontinuation gap. 
 
Study II assessed MPR and persistence for 18 months (exposure period). MPR 
was divided into five levels (i.e., 0%–20%, 21%–40%, 41%–60%, 61%–80 
and 81%–100%) and patients with a discontinuation gap during the exposure 
period were classified as nonpersistent. Study IV assessed MPR for each 
subsequent interval and was categorized as high or low based on an 80% cutoff. 
3.4.4 Guideline adherence 
Study IV defined exposure to CV events and mortality as healthcare providers’ 
adherence to treatment guidelines (i.e., guideline adherence) regarding 
prescriptions for lipid-lowering medications in patients with T2DM. Using 
data from the NDR, we measured guideline adherence as the prevalence of 
lipid-lowering medication prescription among patients with LDL-C above the 
recommended targets levels (i.e., ≥2.5 mmol/l for primary prevention and ≥1.8 
mmol/l for secondary prevention). 
 
Guideline adherence was assessed for each healthcare provider between 2007 
and 2014, and thereafter linked to patients’ intervals based on the year in which 
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the intervals started. For intervals starting in 2006, we used guideline 
adherence for 2007. If information on guideline adherence was missing, we 
imputed the adherence of the preceding year. If no preceding guideline 
adherence was present, we imputed the mean annual guideline adherence from 
the healthcare provider’s county council and type of care. We categorized 
guideline adherence as high or low based on a cutoff representing the median 
guideline adherence for primary and secondary prevention (48% and 78%), 
respectively. 
3.5 Outcomes 
3.5.1 Cardiovascular events 
In Study II and Study IV, outcomes of interest encompassed CV events, which 
included unstable angina pectoris, myocardial infarction (including PCI and 
CABG), ischemic heart disease, and stroke. Data were collected from the 
National Patient Register using ICD and surgical procedure codes (Table 1, 
Paper II and Table S1, Paper IV). 
3.5.2 Mortality 
We retrieved date and cause of death from the Cause of Death Register and 
defined all-cause mortality as death due to any cause. CV mortality was 
defined as death from CVD as the main or contributing cause of death, or 
registration of a CV event in the National Patient Register within 28 days prior 
to death. 
3.5.3 Refill adherence and persistence 
Study I considered refill adherence and persistence as outcomes of interest. 
Refill adherence was measured using the MPR and the maximum gap method 
(Section 3.4.3). Persistence represented the time between the index date and 
the first occurring discontinuation gap (Section 3.4.3). 
3.5.4 Guideline adherence 
Study III examined prevalence of lipid-lowering medication prescription and 
defined guideline adherence as the probability of prescribing lipid-lowering 
medications for patients with T2DM and LDL-C above the recommended 
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target values. Adjusted for patients’ and healthcare providers’ characteristics 
(i.e., risk factors), we presented guideline adherence as crude and adjusted 
rates. We also presented odds ratios for included risk factors for primary and 
secondary prevention, respectively. 
 
This measure of guideline adherence differs from that used as an exposure in 
Study IV (Section 3.4.4). Study IV considered guideline adherence as the 
prescription prevalence of lipid-lowering medications since the probability of 
prescription for each healthcare provider and year was not methodological 
feasible. 
3.6 Covariates 
3.6.1 Patient characteristics 
Patient characteristics included demographics (age, sex, country of birth), 
socioeconomic status (marital status, income, education level, employment 
status, profession), clinical characteristics (diabetes duration, glycated 
hemoglobin [HbA1c], estimated glomerular filtration rate [eGFR], blood 
pressure, cholesterol levels, microalbuminuria, macroalbuminuria, body mass 
index [BMI], kidney disease, cancer), concurrent medications (diabetes 
medications, antihypertensives anticoagulants or antiplatelets), and health-
related characteristics (smoking, physical activity). Figure 3 shows the data 
source for each covariate. 
 
We did not link sex and country of birth to calendar time. Age was calculated 
based on birth year and year of data collection. Marital status was categorized 
as unmarried, married/registered partner, divorced, and widow/widower. 
Employment status was collected as a binary variable and was categorized as 
employed, unemployed, or retired. Retirement described patients who were 
unemployed and at least 65 years of age. 
 
Professions were defined according to the Swedish Standard Classification of 
Occupations, which is based on the International Standard Classification of 
Occupations (ISCO) [89]. We categorized professions as upper white collar, 
lower white collar, blue collar, and other. Our categorization highly 
corresponds to the ISCO. 
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Income was collected as individual and family disposable income as well as 
disposable income per household member. Individual and family incomes 
represented the annual income for the individual and family, respectively. The 
disposable income per household member represented the annual family 
income divided by weighted units of consumption [89]. 
 
Figure 3. Variables collected from respective registers 
We calculated diabetes duration based on birth year and year of diabetes 
diagnosis. eGFR was calculated according to the Modification of Diet 
in Renal Disease equation, which is based on patient’s sex, age, and creatinine 
level. Microalbuminuria and macroalbuminuria were provided as binary 
variables. The diagnosis criteria for microalbuminuria was an 
albumin/creatinine ratio of 3–30 mg/mmol, albumin >200µg/min, or 20-300 
mg/l, in two out of three tests within one year. Macroalbuminuria was defined 
as positive testing for an albumin/creatinine ratio >30 mg/mmol, albumin 
>200µg/min, or >300 mg/l. 
 
• Sex (study I, II, IV)
• Age (study I, II, IV)
• Country of birth
• Marital status
• Education level
• Profession 
• Employment status
• Income
• Migration
• CVD (study I, II, IV)
• Cancer (study I, II)
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If total cholesterol, high-density lipoprotein cholesterol (HDL-C), and 
triglycerides were reported to the NDR concurrently, LDL-C was calculated 
using the Friedwald equation; otherwise the reported value of LDL-C was 
used. Smoking was defined as at least one cigarette or pipe per day or stopped 
smoking within three months. Physical activity was defined as a 30-minute 
walk (or equivalent) and categorized as less than once a week, 1–2 times per 
week, 3–5 times per week, or daily. 
 
In Study I and Study II, we collected cancer diagnoses from the National 
Patient Register and defined cancer as any malignant tumor (ICD codes C00–
C97) registered within five years prior to the index date. Study IV collected 
cancer diagnoses from the Swedish Cancer Registry and defined cancer as any 
primary tumor (ICD codes C00–C97) registered within five years prior to the 
baseline date. 
 
Study I, Study II, and Study IV defined concurrent medications as filled 
prescriptions for diabetes medications (ATC: A10), antihypertensives (ATC: 
C02, C07, C08, C09) and anticoagulants (ATC: B01), collected from the 
SPDR. Study III defined concurrent medications as use of diabetes medications 
(ATC: A10), antihypertensives (ATC: C02, C07, C08, C09) and antiplatelets 
(ATC: B01AC, N02BA01), as reported in the NDR. 
 
Study IV collected diagnoses of kidney disease from the National Patient 
Register and defined kidney disease as acute or chronic kidney failure as well 
as glomerular or renal complications due to T2DM. For ICD codes, see Table 
S1, Paper IV. 
3.6.2 Healthcare provider characteristics 
Study III and Study IV used NDR data to determine the characteristics of 
healthcare providers. We gathered data about healthcare providers at 
healthcare facility level. Hence, no individual practitioners were identified. 
Healthcare providers were categorized as primary or specialized care 
providers, and according to county council. 
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3.7 Statistical methods 
3.7.1 Statistical methods used in the studies 
Study I analyzed differences in MPR and persistence by prevention group in 
three models. Model 1 adjusted for age, sex, and socioeconomic status; Model 
2 adjusted for age, sex, socioeconomic status, and concurrent medications; and 
Model 3 adjusted for age, sex, socioeconomic status, concurrent medications, 
and clinical characteristics. We used multivariable linear regression models to 
analyze differences in MPR. Risk of discontinuation (i.e., difference in 
persistence) was analyzed using Cox proportional hazard regression and 
Kaplan-Meier (KM) survival analysis. Using logistic regression, we analyzed 
difference in nonadherence by prevention groups according to the maximum 
gap method. 
 
In Study II, we used Cox proportional hazard regression and KM survival 
curves to analyze risk of CV event and mortality by five levels of MPR as well 
as by persistence. We studied data about primary and secondary prevention 
patients separately, and replaced missing data using multivariate imputations 
by chained equations (MICE) [94, 95]. Additionally, we compared results from 
imputed data with results from complete cases. 
 
Study III used mixed-effect model regression to analyze the annual probability 
of prescribing lipid-lowering medications for T2DM patients with LDL-C 
exceeding recommended target levels. We also used mixed-effect model 
regression and odds ratio to assess the odds of prescribing lipid-lowering 
medications for all patient and healthcare provider characteristics. In the 
mixed-effect models, prescription for lipid-lowering medications was 
considered the response, LDL-C and CVD were considered exposures, and the 
unique person identifier was considered a fixed effect. 
 
Study IV used general linear regression to analyze the association between 
MPR and guideline adherence. The risk of CV event and mortality was 
analyzed for each subsequent interval using Cox proportion hazard regression 
and KM survival curves, adjusted for potential confounders. Covariates and 
guideline adherence for one interval were considered potential confounders for 
the subsequent interval of MPR measures. Likewise, MPR for one interval was 
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considered the exposure for the subsequent interval of outcome measures 
(Figure S2, Paper IV). 
 
We performed multiple imputations using R version 3.3.2 [96] and the MICE 
package [94]. All other data management and analyses were performed using 
SAS software version 9.4 (SAS institute, Cary NC). 
3.7.2 Logistic and linear regression 
Both logistic and linear regression models measure the association between a 
dependent variable and one or more categorical and/or continuous independent 
variables (e.g. sex, physical activity, age, diabetes duration etc.). While the 
dependent variable in linear regression is continuous (e.g., MPR), logistic 
regression has a binary dependent variable (e.g., adherent, year or no). 
3.7.3 Cox Proportional Hazard Regression 
Survival analysis follows individuals to examine time of an event (e.g., disease, 
death, etc.). Individuals who do not experience the event of interest during the 
study period are called censored. Reasons for censoring may be due to 
migration or end of the study. Cox proportional hazard is a regression model 
that analyzes the association between patients’ survival time and several risk 
factors on survival time. This specific regression model allows us to examine 
differences in survival between patient groups and for specific risk factors that 
influence the rate of a particular event happening at a particular point in time. 
 
Hazard function can be interpreted as the risk of an event at a specific time 
point. Results from the regression model are shown as hazard ratios (HR), 
which represents the ratio of the hazard for one group compared to another 
group. HRs above 1 indicates a positive association between a covariate and 
event probability and thus a negative association with the survival length. The 
opposite applies to HRs below 1, which indicate a positive association to 
survival length. HRs equal to 1 indicate no association between covariate and 
event probability and thus no association with survival length. 
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3.7.4 Kaplan-Meier 
The KM survival curves visualize survival of an event over time. Generating 
KM estimators for different patient categories requires event status (event 
occurrence or censored), time to event (or time to censoring), and group 
assignment (e.g., treatment, yes or no). KM estimators can be derived from the 
Cox proportional hazard regression model and thus provide survival curves 
adjusted for several risk factors. 
3.7.5 Mixed-effect models 
Mixed-effect models use both fixed and random effects in the same analysis. 
Thus, such models provide a flexible approach when analyzing data from 
longitudinal studies with repeated measures per individual as they allow for a 
variety of correlations patterns. 
3.7.6 Missing data and multiple imputation 
Missing data refers to observations where one or more variables lack 
information, resulting in incomplete data sets. Multiple imputations involve 
filling in these missing data according to observed information for the given 
individual and the relations in data from other individuals in the data set. This 
technique involves imputing missing values multiple times, analyzing imputed 
data sets, and pooling of results (Figure 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Multiple imputation process 
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MICE is a multiple imputations technique that runs a series of regression 
models [94, 95]. The variables that is to be imputed is used as a dependent 
variable; all other covariates are considered independent. Missing values are 
replaced with predictions (i.e., imputations) from the regression model. When 
the missing value of one variable has been replaced, that variable is later used 
as an independent variable in the imputation of another variable. The same 
procedure is performed for all variables with missing information. When all 
missing values have been replaced with predictions, one iteration has been 
performed. Several iterations are performed to allow convergence (i.e. 
stability) of the distribution of coefficients in the regression models. In this 
way, the order of imputation is less important. At the end of the iterations, the 
final predictions are retained, and a complete imputed data set is achieved. The 
entire imputation process is repeated several times to achieve multiple 
imputation. The imputed data sets are used in the statistical analysis and results 
are achieved for each data set. Thereafter, the results are pooled to give a final 
result. 
3.8 Ethical considerations 
The Regional Ethical Review Board in Gothenburg has approved all studies of 
this thesis with following reference numbers: 563-12 (Study I), 776-14 (Study 
II), 1173-16 (Study III), and 312-17 (Study IV). 
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4 RESULTS 
4.1 Study I 
Study I included data about of 97,595 patients, 77% of whom had no 
established CVD prior to inclusion and thus were assigned to lipid-lowering 
primary prevention. For patient characteristics, see Table 2, Paper I. 
 
Mean MPR was 71% in the total population, 69% among primary prevention 
patients and 76% among secondary prevention patients (Table 2, Paper I). The 
maximum gap method determined that 64% of primary prevention patients and 
52% of secondary prevention patients were nonadherent. Around 70% of all 
patients were persistent for at least one year and around 50% were still filling 
prescriptions for lipid-lowering medications after three years. Twenty-five per 
cent of those who discontinued treatment did so within the first year. Thereafter 
the discontinuation rate decreased to 5% during the third year. 
 
After adjusting for potential confounders, the MPR of secondary prevention 
patients was 3–6 percentage higher compared to primary prevention patients 
(Table 3, Paper I). Compared to patients born in Sweden, those who were born 
if another European country or the Soviet Union, or in Africa or the Americas 
had between 3 and 12 percentage lower MPR. Compared to patients without 
diabetes medications, the MPR of those who filled prescription for glucose-
lowering medication other than insulin was around 4 percentage higher. 
Furthermore, MPR was around 4 percentage higher in nonsmoking patients. 
Although several characteristics showed statistically significant results, we 
considered differences around 5 percentages as clinically relevant. 
 
In the fully adjusted model, secondary prevention patients showed lower risk 
of premature discontinuation of treatment (HR=0.91) compared to primary 
prevention patients (Table 3, Paper I). The pattern of difference in risk of 
discontinuation was similar to that for difference in MPR. Patients born in 
another European country or the Soviet Union (HR=1.16–1.25), or Africa 
(HR=1.64), or the Americas (HR=1.81) all had higher risk of discontinuing 
treatment. Moreover, patients with glucose-lowering medication other than 
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insulin (HR=0.84) and nonsmokers (HR=0.82) showed lower risk of 
discontinuation. 
 
Compared to primary prevention patients, the KM survival curves showed 
higher persistence rates among secondary prevention patients in all three 
models (Figure 2, Paper I). 
4.1.1 Differences between men and women 
Among primary prevention patients, mean MPR was 70% for men and 69% 
for women (Table 2). The corresponding numbers for secondary prevention 
patients were 77% for men and 74% for women. The proportion of patients 
with treatment gaps of at least 45 days was similar within the prevention 
groups. Among secondary prevention patients, men showed higher persistence 
to treatment compared to women. Persistence was similar in the primary 
prevention group. KM survival curves from the fully adjusted model showed 
higher persistence among male secondary prevention patients, compared to no 
difference in women’s persistence between the prevention groups (Figure 5). 
 
Table 2. Refill adherence and persistent by gender in study I 
 Primary prevention n=75,464 
Secondary prevention 
n=22,131 
 Men (n=41,931) 
Women 
(n=33,533) 
Men 
(n=14,465) 
Women 
(n=7,666) 
MPR (%) n (%) n (%) n (%) n (%) 
≤20 5,114 (12.2) 4,679 (14.0) 1,149 (7.9) 868 (11.3) 
21-40 4,406 (10.5) 3,566 (10.6) 1,118 (7.7) 685 (8.9) 
41-60 4,203 (10.0) 3,167 (9.4) 1,152 (8.0) 589 (7.7) 
61-80 6,176 (14.7) 4,383 (13.1) 1,670 (11.6) 825 (10.8) 
>80 22,032 (52.5) 17,738 (52.9) 9,376 (64.8) 4,699 (61.2) 
Mean (SD) 69.6 (30.7) 68.8 (32.1) 77.4 (28.4) 74.3 (31.2) 
Median (IQR) 81.9 (---) 82.2 (---) 91.4 (---) 91.1 (---) 
 
Treatment gaps ³45 days 
Nonadherent 26,993 (64.4) 21,244 (63.4) 7,404 (52.2) 4,015 (52.3) 
 
Persistence 
One year 30,424 (72.6) 24,008 (71.6) 10,975 (75.9) 5,335 (69.5) 
Two years 25,845 (61.6) 20,231 (60.6) 9,180 (63.5) 4,318 (56.3) 
Three years 24,041 (57.3) 18,790 (56.0) 8,309 (57.4) 3,814 (49.8) 
Mean days (SD) 761.7 (420.7) 751.1 (424.1) 784.5 (403.7) 717.8 (423.4) 
Median days 1,095 (---) 1,095 (---) 1,095 (---) 1,063 (---) 
MPR, medication possession ratio 
?? ?
?
?
?
?
?????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????
?
?
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4.2 Study II 
Study II followed 86,568 patients, of whom 86.5% had initiated lipid-lowering 
primary prevention at inclusion. For patient characteristics, see Table 2, Paper 
II. Mean MPR was 77% among primary preventions; 78% were persistent 
during the 18-month exposure period. Among secondary prevention patients, 
mean MPR was 83%; 83% were persistent for 18 months. 
 
Compared with patients with MPR >80%, the risk of any CV event gradually 
increased with lower MPR level, independent of prevention group (Table 3, 
Paper II). Greatest risk was observed for myocardial infarction. Compared to 
patients with MPR >80%, the risk of myocardial infarction ranged from 39% 
to three-folded increased risk among primary prevention patients and between 
40% to two-folded increased risk among secondary prevention patients. The 
risk of all-cause and CV mortality was higher among patients with MPR ≤80%, 
compared to those with MPR >80%. However, we observed no clear trend 
between the MPR levels. 
 
Furthermore, risk of CV events and CV mortality was 64% and 15% higher in 
nonpersistent primary prevention patients compared to persistence patients, 
respectively (Table 4, Paper II). The corresponding numbers for nonpersistent 
secondary prevention patients was 33% and 29% higher, respectively. 
 
Adjusted for potential confounders, KM survival curves shows higher survival 
of any CV event with higher MPR levels in both prevention groups (Figure 2, 
Paper II). For all-cause mortality, the survival curves were similar between the 
MPR levels. 
4.2.1 Differences between men and women 
Both prevention groups showed little difference in mean MPR between the 
sexes (Table 3). Among primary prevention patients, 6% of men and 4% of 
women experienced a CV event during the study period, and around 2% of 
both men and women died. CV mortality accounted for 58% of deaths among 
men compared to 48% among women. In secondary prevention patients, 40% 
of men and 49% of women experienced a CV event, 29% of men and 42% of 
 31 
women died, and CV mortality constituted 33% and 29% of all deaths in men 
and women, respectively. 
 
Table 3. MPR divided by prevention group and sex 
 Primary prevention n=74,909 
Secondary prevention 
n=11,659 
 Men n=41 470 
Women 
n=33 439 
Men 
n=7 676 
Women 
n=3 983 
MPR n (%) n (%) n (%) n (%) 
≤20% 2,652 (6.4) 2,232 (6.7) 378 (4.9) 220 (5.5) 
21–40% 3,508 (8.5) 2,660 (8.0) 417 (5.4) 249 (6.3) 
41–60% 4,132 (10.2) 3,259 (9.8) 539 (7.0) 331 (8.3) 
61–80% 6,110 (14.7) 4,469 (13.4) 884 (11.5) 459 (11.5) 
>80% 24,969 (60.2) 20,819 (62.3) 5,458 (71.1) 2,724 (68.4) 
Mean (SD) 77.1 (26.4) 77.9 (26.8) 83.2 (24.2) 81.7 (25.6) 
Median (IQR) 89.9 (38.8) 90.9 (38.0) 95.8 (27.1) 95.4 (27.8) 
MPR, medication possession ratio 
 
After adjusting for potential confounders, we noticed a trend of gradually 
higher risk of any CV event with lower MPR level in both sexes and prevention 
groups (Tables 4 and 5). However, we observed no statistically significant 
difference among primary prevention women with MPR 61%–80%. In both 
prevention groups, the risk of all-cause and CV mortality was higher in patients 
with MPR ≤80%. However, no clear trend was observed among MPR levels. 
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4.3 Study III 
Study III included 1,204,376 observations from 322,046 T2DM patients 
reported by 1,325 healthcare providers (Figure 1, Paper III). Sixty-three per 
cent of all observations were attributed to lipid-lowering primary prevention. 
For patient characteristics see, Table 1, Paper III. 
 
Between 2007 and 2014, prevalence of lipid-lowering medication prescription 
for patients with LDL-C above recommended target levels ranged 40%–49% 
in the primary prevention group and 72%–78% in the secondary prevention 
groups, respectively (Figure 2, Paper III). Adjusted guideline adherence 
increased from 36% in 2007 to 46% in 2014 for primary prevention and from 
59% to 66% for secondary prevention. 
 
Independent of prevention group, the odds of receiving a prescription for lipid-
lowering medications was generally higher in patients who were treated by 
specialized healthcare providers (Figures 3 and 4, Paper III). Furthermore, we 
observed higher odds in patients who were physically active more than once a 
week, smokers, and those with concurrent prescriptions for other 
cardioprotective medications. In primary prevention patients, the odds of 
receiving lipid-lowering medications were lower for men and patients aged 80 
years or older and higher with increasing diabetes duration. Among secondary 
prevention patients, odds were higher for men and lower with increasing 
diabetes duration. 
4.3.1 Differences between men and women 
Forty-one percent of all observations among men were attributed to secondary 
prevention compared to 32% among women. Between 2007 and 2014, the 
prevalence of receiving a prescription for lipid-lowering medications was 
52%–60% and 55%–62% for primary prevention men and women, 
respectively (Table 6). For secondary prevention patients, the corresponding 
ranges were 77%–82% and 73%–78% for men and women, respectively. 
Among primary prevention patients, healthcare providers’ guideline adherence 
to lipid-lowering medication prescription was initially higher among female 
primary prevention patients. After leveling off, the guideline adherence 
remained similar between the sexes (Tables 7). Adjusted for potential 
 35 
confounders, guideline adherence among secondary prevention patients 
showed similar rates between the sexes over time (Table 8). 
 
Table 6. Prevalence of lipid-lowering medication prescription by year, categorized by 
prevention group and sex 
 Primary Prevention Secondary Prevention 
Year Men n (%) 
Women 
n (%) 
Men 
n (%) 
Women 
n (%) 
2007 21,057 (51.5) 19,095 (54.6) 15,051 (76.9) 8293 (73.2) 
2008 27,319 (54.7) 24,833 (57.4) 19,632 (79.2) 10,924 (75.0) 
2009 35,661 (57.5) 31,484 (59.8) 25,902 (81.1) 14,420 (77.2) 
2010 57,101 (59.3) 51,737 (61.5) 41,068 (81.5) 23,511 (77.7) 
2011 72,578 (59.9) 64,964 (61.5) 52,124 (82.3) 29,206 (77.9) 
2012 72,723 (59.5) 62,825 (60.5) 51,366 (81.4) 28,243 (76.7) 
2013 64,399 (58.6) 53,893 (58.9) 45,704 (79.7) 23,986 (73.7) 
2014 65,559 (57.5) 53,041 (56.8) 50,066 (79.1) 25,784 (73.6) 
 
 
  
Table 7. Probability of prescribing lipid-lowering medication in primary prevention patients 
 Men Women 
Year 
Crude 
probability 
(95% CI) 
Adjusted 
probability 
(95% CI) 
Crude 
probability 
(95% CI) 
Adjusted 
probability 
(95% CI) 
2007 33.5 (32.8–34.1) 33.7 (31.9–35.5) 37.3 (36.6–38.0) 38.7 (36.6–40.9) 
2008 38.2 (37.6–38.7) 38.1 (36.3–39.8) 41.3 (40.7–41.9) 42.6 (40.5–44.7) 
2009 42.3 (41.7–42.8) 42.1 (40.3–43.9) 44.7 (44.1–45.3) 45.6 (43.5–47.79 
2010 44.4 (43.9–44.9) 45.1 (43.3–46.9) 46.6 (46.0–47.1) 47.6 (45.5–49.7) 
2011 47.0 (46.5–47.5) 46.3 (44.4–48.1) 48.0 (47.5–48.6) 46.9 (44.8–49.0) 
2012 48.2 (47.7–48.7) 46.6 (44.7–48.4) 48.1 (47.6–48.6) 46.6 (44.5–48.8) 
2013 48.9 (48.4–49.4) 46.9 (45.0–48.8) 47.8 (47.2–48.3) 46.3 (44.1–48.4) 
2014 49.9 (49.4–50.5) 46.2 (44.3–48.1) 48.2 (47.6–48.7) 46.0 (43.8–48.1) 
Table 8. Probability of prescribing lipid-lowering medication in secondary prevention patients 
 Men Women 
Year 
Crude 
probability 
(95% CI) 
Adjusted 
probability 
(95% CI) 
Crude 
probability 
(95% CI) 
Adjusted 
probability 
(95% CI) 
2007 72.2 (71.67–2.8) 58.0 (55.7–60.4) 68.2 (67.4–69.1) 59.9 (56.8–62.8) 
2008 74.6 (74.0–75.1) 62.8 (60.6–65.0) 70.1 (69.3–70.8) 63.5 (60.7–66.3) 
2009 76.3 (75.8–76.8) 66.0 (63.8–68.0) 72.1 (71.5–72.7) 66.8 (64.2–69.4) 
2010 76.6 (76.2–77.0) 68.5 (66.4–70.5) 71.7 (71.1–72.3) 67.4 (64.7–70.0) 
2011 77.3 (76.9–77.7) 69.3 (67.3–71.3) 71.5 (71.0–72.1) 69.4 (66.8–71.9) 
2012 75.9 (75.5–76.3) 68.1 (66.0–70.1) 69.6 (69.1–70.2) 67.9 (65.2–70.4) 
2013 74.5 (74.1–75.0) 66.7 (64.6–68.8) 67.3 (66.7–67.9) 66.8 (63.9–69.5) 
2014 73.7 (73.3–74.2) 66.5 (64.3–68.5) 66.2 (65.6–66.9) 65.3 (62.5–68.0) 
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With some exceptions, the odds of receiving a prescription for lipid-lowering 
medications were similar between the sexes within the prevention groups. In 
the primary prevention group, odds were higher among men receiving diabetes 
medications and/or antiplatelets and also for those treated within specialized 
care. Additionally, women smokers and those aged 46–60 years showed higher 
odds (Table 9). In secondary prevention, higher odds were observed among 
men with antiplatelets as well as smoking women. 
 
Table 9. Odds ratios for primary prevention men and women 
 Primary prevention Secondary prevention 
 Men Women Men Women 
Factors OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Specialized vs. primary care 1.24 (1.15–1.33) 1.05 (0.96–1.14) 1.44 (1.29–1.60) 1.39 (1.22–1.59) 
Age, 46–60 years vs. <45 years 0.98 (0.95–1.02) 1.12 (1.08–1.16) 0.90 (0.85–0.96) 0.91 (0.83–1.00) 
Age, 61–80 years vs. <45 years 0.51 (0.47–0.55) 0.57 (0.54–0.61) 0.49 (0.46–0.54) 0.48 (0.44–0.54) 
Diabetes duration, 5–10 years vs. <5 years 1.18 (1.14–1.21) 1.14 (1.11–1.18) 0.90 (0.86–0.95) 0.93 (0.88–0.98) 
Diabetes duration, >10 years vs. <5 years 1.20 (1.16–1.25) 1.17 (1.12–1.21) 0.81 (0.77–0.86) 0.88 (0.82–0.94) 
HbA1c, high vs. low 1.03 (1.01–1.06) 1.05 (1.02–1.07) 1.09 (1.06–1.13) 1.01 (0.97–1.06) 
Diabetes medication, yes vs. no 1.58 (1.53–1.64) 1.50 (1.45–1.56) 1.43 (1.36–1.50) 1.43 (1.35–1.52) 
Antihypertensives, yes vs. no 1.87 (1.81–1.94) 1.88 (1.81–1.95) 3.11 (2.90–3.34) 2.95 (2.71–3.21) 
Antiplatelets, yes vs. no 1.93 (1.86–2.01) 1.79 (1.72–1.87) 2.50 (2.38–2.63) 2.12 (2.01–2.25) 
Systolic blood pressure, high vs. low 0.96 (0.94–0.99) 0.99 (0.96–1.01) 0.96 (0.93–0.99) 0.98 (0.94–1.01) 
Diastolic blood pressure, high vs. low 0.95 (0.93–0.98) 0.98 (0.95–1.00) 0.95 (0.92–0.98) 0.94 (0.91–0.97) 
Total cholesterol, high vs. low 0.94 (0.91–0.97) 0.92 0.87–0.97) 0.80 (0.77–0.83) 0.79 (0.75–0.83) 
HDL cholesterol, high vs. low 1.19 (1.15–1.23) 1.15 (1.12–1.18) 1.17 (1.12–1.22) 1.06 (1.01–1.11) 
Triglycerides, high vs. low 1.18 (1.15–1.22) 1.16 (1.13–1.20) 1.12 (1.08–1.17) 1.19 (1.14–1.25) 
eGFR, high vs. low 1.04 (0.99–1.09) 1.02 (0.98–1.05) 1.03 (0.98–1.07) 0.96 (0.92–1.01) 
Microalbuminuria, yes vs. no 1.04 (1.01–1.08) 1.03 (0.99–1.07) 1.03 (0.99–1.08) 0.99 (0.94–1.05) 
Macroalbuminuria, yes vs. no 1.05 (0.97–1.15) 1.11 (0.99–1.23) 0.88 (0.81–0.95) 0.90 (0.80–1.01) 
BMI, high vs. low 1.02 (0.99–1.05) 0.96 (0.93–0.99) 1.11 (1.06–1.16) 1.04 (0.99–1.09) 
PA, 1–2 times/week vs. less than once/week 1.05 (1.02–1.08) 1.05 (1.02–1.09) 1.09 (1.05–1.14) 1.13 (1.08–1.19) 
PA, 3–5 times/week vs. less than once/week 1.03 (0.99–1.06) 1.07 (1.04–1.11) 1.13 (1.08–1.18) 1.21 (1.15–1.28) 
PA, daily vs. less than once/week 1.01 (0.98–1.05) 1.06 (1.03–1.10) 1.10 (1.05–1.15) 1.23 (1.16–1.29) 
Smoking, yes vs. no 1.08 (1.04–1.13) 1.20 (1.15–1.25) 1.05 (0.98–1.11) 1.32 (1.22–1.43) 
BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; 
PA, physical activity. 
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4.4 Study IV 
Study IV included 123,460 patients, 88% of whom had initiated lipid-lowering 
medications for primary prevention. For patient characteristics, see Table 1, 
Paper IV. 
 
Compared to high-adherent patients (MPR above 80%), primary prevention 
patients with low refill adherence (MPR 80% or less) showed 41%–49% higher 
risk of experiencing a CV event, 35% higher risk of all-cause mortality, and 
37%–39% higher risk of CV mortality (Table 2, Paper IV). Compared to those 
treated by high-adherent healthcare providers, low-adherent patients showed 
an 8% increased risk of CV events and an 11% increased risk of CV mortality. 
Additionally, high-adherent patients showed an 13% increased risk of CV 
mortality. Otherwise, we observed no statistically significant difference 
between guideline adherence levels. 
 
Compared to high-adherent patients, secondary prevention patients with low 
refill adherence had 16%–19% higher risk of CV event, 33–34%% higher risk 
of all-cause and CV mortality (Table 2, Paper IV). We observed no statistically 
difference in risk of outcome dependent on guideline adherence level among 
secondary prevention patients. 
 
With some exceptions, generally the risk of experiencing a CV event or 
mortality was higher with increasing age and diabetes duration, among 
smokers and with lower income per household member as well as lower kidney 
function (Table 3, Paper IV). Lower risk was observed among those who were 
born outside of Sweden, who filled prescriptions for anticoagulants or 
antihypertensives, or with higher HDL-C or BMI. 
4.4.1 Differences between men and women 
Compared to women, male primary prevention patients showed 57% higher 
risk of experience a CV event, 38% higher risk of all-cause mortality, and 54% 
higher risk of CV mortality (Table 3, Paper IV). Corresponding risk for male 
secondary prevention patients were 34% higher for CV events, 46% higher for 
all-cause mortality, and 48% higher for CV mortality. Aside from the 
differences in risk of outcomes between the sexes, the general pattern of higher 
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risk among low-adherent patients regardless of guidelines adherence level was 
observed among men and women, in both prevention groups. 
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5 DISCUSSION 
5.1 Main findings 
5.1.1 Refill adherence and persistence 
In Study I, overall mean MPR was 71%, and 55% of patients had an MPR 
greater than 80%. More than 70% of all patients were persistent for at least one 
year and more than 50% were still filling prescription for lipid-lowering 
medication after three year. Similar results have been observed in previous 
studies among patients with DM or established CVD [97-100]. However, most 
studies report 12-month MPR, meaning adherence was higher among our study 
population during a 3-year period. Furthermore, the discontinuation rate was 
higher during the first year after initiation and decreased during the second and 
third year. The same findings have been observed in studies from Finland [98] 
and the Netherlands [99]. 
 
On average, patients with previous CVD who received treatment with lipid-
lowering secondary prevention showed higher refill adherence compared to 
primary prevention patients, even after adjusting for potential confounders. 
Moreover, the maximum gap method showed that primary prevention patients 
were more likely to be nonadherent. However, our results showed little 
difference in persistence, suggesting that most T2DM patients were persistent 
to their lipid-lowering medications for up to 3 years, independent of prevention 
group. However, primary prevention patients tended to have longer periods of 
insufficient medication supplies without prematurely discontinuing treatment. 
 
The greatest difference in refill adherence and risk of discontinuation of 
treatment occurred in patients who were born in Africa or the Americas. 
Although these patients represented only 2% of the total study population, it is 
important to identify patient groups at risk of nonadherence to achieve optimal 
use of medications. 
5.1.2 Guideline adherence 
In Study III and Study IV (2007–2014), prevalence of lipid-lowering 
medication prescription among patients with T2DM and risk-associated LDL-
C values was higher in the secondary prevention group compared to primary 
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prevention. This was expected because the LDL-C target level for secondary 
prevention is lower (1.8 mmol/l vs. 2.5 mmol/l) and guidelines highly 
recommend lipid-lowering medications in the treatment regimen following 
myocardial infarction or stroke [50, 51]. Similar results have been observed in 
previous studies, which report higher adherence to guidelines among patients 
attributed to secondary prevention or in primary prevention patients with risk 
factors associated with higher risk of CVD [21, 22, 63, 65, 66]. 
 
The adjusted probability of prescribing lipid-lowering medications (i.e., 
guideline adherence in Study III), increased between 2007 and 2011, and then 
levelled off in both prevention groups. This suggest a fairly consistent 
prescription pattern among Swedish healthcare providers with only small year-
to-year fluctuations. Furthermore, the odds of receiving a prescription for lipid-
lowering medications was higher among patients whose characteristics usually 
associate with increased CVD risk (e.g., men, concurrent prescription of other 
cardioprotective medications, smoking, etc.). Our findings are in line with 
previous research that reports varying guideline adherence to lipid-lowering 
medication prescription between primary and secondary prevention among 
T2DM patients, as well as the association between prescription and CVD risk 
factors [21, 22, 63-66]. Thus, healthcare providers treating T2DM in Sweden 
seem to have based the prescription for lipid-lowering medication on more than 
the LDL-C value alone, as suggested by the guidelines. 
 
In Study IV, healthcare providers’ level of guideline adherence showed little 
or no impact on patients’ risk of CV events or death, regardless of prevention 
group. However, in our assessment of guideline adherence lipid-lowering 
medication prescription was used as a binary variable. Hence, we did not 
consider prescribed medication class or strength and thus not treatment 
intensity. Furthermore, we did not consider conditions that may have been 
contraindicated for lipid-lowering medications use, or patients’ experience of 
adverse drug reactions due to such medications. Therefore, we may have 
underestimated healthcare providers’ adherence to lipid-lowering prescription 
guidelines. 
 
Healthcare providers’ adherence to guidelines showed little or no impact on 
patients’ refill adherence. However, we did not consider other healthcare 
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professions patients may encounter in their diabetes care (e.g., nurses, 
dieticians, physical therapists, pharmacists, etc.). In fact, healthcare providers’ 
attitudes and beliefs concerning management of diabetes have shown to 
influence T2DM patients self-management behaviors, and those with access to 
a diabetes team, group training programs, or specialized diabetes nurses had 
better HbA1c control [23, 101]. 
 
Importantly, level of guideline adherence does not equal quality of care. 
Examples of extremes include healthcare providers with low guidelines 
adherence who mostly treat patients with severe diseases that may be 
contraindicated for lipid-lowering medications. In this context, the healthcare 
provider is acting according to guidelines, but our study identified this a 
nonadherence. Another extreme is a healthcare provider who prescribes lipid-
lowering medications to every patient who fits guideline recommendations 
because the provider feels obligated to do so. In this context, the healthcare 
provider adheres to guidelines, but we know nothing about the communication 
between provider and patients. Hence, we do not know if the provider informed 
patients about the medications or the reasons for the prescription. 
5.1.3 Risk of CV events and mortality 
Study II showed increased risk of CV events among patients with low levels 
of refill adherence (MPR 80% or less), compared to those with high level of 
refill adherence (MPR above 80%). This concur with previous studies [32, 67-
77]. However, we also found the risk of CV events to increase gradually in 
relation to level of refill adherence in both prevention groups, suggesting that 
risk of CV events changes when refill adherence levels are below 80%. 
Although previous studies frequently categorized patients as adherent or not 
based on the 80% cutoff our data suggests that dividing MPR by more than 
these two levels better portrays the difference in risk between patients with less 
than complete adherence. 
 
Importantly, the level of refill adherence tells little about patients’ actual 
pattern of medication use, especially in a lengthy study period. Each level of 
MPR below 80% includes patients who occasionally forget to take their 
medications or actively choose to prematurely discontinue treatment. In Study 
II, an MPR of 41%–60% included patients who took their medications every 
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other day as well as those who discontinued treatment halfway through the 
study period. 
 
In Study IV, level of refill adherence seemed more important than level of 
guideline adherence regarding risk of CV events and mortality. Independent of 
providers’ level of guideline adherence, patients with high refill adherence 
showed lower risk of CV event and mortality compared to patients with low 
refill adherence. However, we observed no statistically significant difference 
in risk among low- or high-adherent patients based on the guideline adherence 
level except in primary prevention patients who were treated by low-adherent 
healthcare providers. This should not be interpreted as healthcare providers’ 
adherence to treatment guidelines are unimportant as prescribing is a 
prerequisite for medication use among patients. Thus, healthcare providers 
should not refrain from prescribing lipid-lowering medications according to 
guidelines. 
5.1.4 Differences between men and women 
Adjusted for potential confounders, men showed higher odds of receiving a 
prescription for lipid-lowering medications in both prevention groups. 
However, little difference was observed in prescription prevalence and 
guideline adherence between the men and women within the prevention 
groups. Furthermore, except for minor differences, patient characteristics 
associated with higher or lower odds or receiving a prescription for lipid-
lowering mediation were similar between the sexes. 
 
In general, men have higher risk of developing CVD compared to women, 
which may explain the higher odds of receiving a prescription for lipid-
lowering medications. Otherwise, our results suggest that the prescription 
process among Swedish healthcare providers is similar among T2DM patients, 
intendent of sex. However, in our assessment of guideline adherence, no 
information about prescribed medication class or strength was considered. 
Hence, do not know if there are differences in choice of treatment between men 
and women with T2DM. 
 
Overall, we observed little difference in refill adherence among men and 
women within the prevention groups. After adjusting for potential 
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confounders, the KM survival curves showed higher persistence among men 
with secondary prevention compared to those with primary prevention. 
However, among women no difference in persistence was observed between 
the prevention groups. Women and patients with primary prevention have 
previously been shown associate with higher risk of nonpersistence to lipid-
lowering medications among T2DM patients [99]. 
 
Risk of CV events and mortality was similar between men and women within 
the prevention groups even at multiple levels of refill adherence. This indicates 
a beneficial effect of higher levels of refill adherence to lipid-lowering 
medications among men and women with T2DM. 
5.2 Methodological considerations 
Internal validity is the ability to draw a causal link between the exposure and 
outcome in a study, whereas external validity is the ability to generalize the 
study findings. In randomized controlled studies, close monitoring of follow-
up and strict inclusion criteria result in patient groups that are as equal as 
possible, thus increasing the internal validity of the study. However, a highly 
selective study population results in limited external validity. Observational 
studies do not randomize patients, contributing to possible bias and low 
validity. However, observational studies reflect the routine of clinical practice, 
which results in high external validity. Thus, randomized controlled studies 
followed by observational studies give a more accurate picture of the causal 
link of a treatment as well as its applicability to clinical practice. 
 
Random and systematic errors may affect the validity of a study. Random 
errors (i.e., statistical fluctuations in data resulting from precision limitations 
of measurements) can be reduced by increasing sample size. Systematic errors 
(i.e., reproducible inaccuracies that point in the same direction due to imperfect 
calibration of measurement devices) may be difficult to detect. Systematic 
errors are not dependent on sample size and include selection bias, information 
bias, and confounding. Selection bias, which occurs when a selected 
population does not represent the targeted population, may result in an 
inaccurate conclusion from the statistical analysis. Information bias arises from 
inaccurate measurement, collection, or interpretation of key information. 
Nondifferential misclassification happens when the information is incorrect 
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across the study population, whereas differential misclassification occurs when 
information errors differ between groups, such as between exposed and 
unexposed (e.g., missing information, incorrect disease codes, etc.). 
Confounding refers to variables that influence both exposure and outcome and 
may provide alternative explanations for an observed association. 
5.2.1 Study design and settings 
Because we linked data between registers using patients’ PIN, our data 
collection was considered complete in relation to the information available at 
the time of collection. Data may be reported to the registers at different times 
or intervals, possibly delaying availability. Thus, time of data collection may 
influence the extraction of data from the registers. The SPDR compiles data on 
a monthly basis. In comparison, reporting cause of death to the Cause of Death 
Register may take longer because the National Board of Health and Welfare, 
which validates the register, may request additional information. However, lag 
time in the registers was not considered an issue due to the large study 
populations in our studies. 
 
The populations of Study I, Study II, and Study IV were collected from the 
same sources and according to similar inclusion and exclusion criteria. 
Differences in study period and time of data collection resulted in varying 
population sizes. Study II and Study IV excluded patients who experienced 
outcomes during the exposure period or first filled prescription, respectively. 
Thus, we may have excluded the most fragile patients and introduced selection 
bias. However, baseline characteristics remained similar between Study I, 
Study II, and Study IV, suggesting stability in the composition of study 
population. 
 
In all studies, patients with T2DM were identified through the NDR. Patient 
coverage in the NDR is almost complete as of today. In relation to the overall 
inclusion period of this thesis, national coverage of patients with DM increased 
from 43% in 2006 to 87% in 2012 [102, 103]. Thus, the study populations in 
this thesis do not represent the true T2DM population of Sweden. However, 
we believe that our large nationwide study populations of T2DM patients 
allowed a realistic assessment of clinical practice for diabetes care in Sweden. 
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5.2.2 Exposures and outcomes 
Study I, Study II and Study IV used SPDR data to assess patients’ behavior 
regarding lipid-lowering medication use. Estimates suggest that the SPDR 
maintains complete coverage of all filled prescriptions from Swedish 
pharmacies [104]. Its data collection process is automated and based on 
administrative systems. Sometimes, in agreement with patients, the dispensing 
process is made in advance to make it easier for patients to collect their 
medications. However, the process needs to be reversed if patients do not 
collect their medications, in order to return the medications to the pharmacy 
storage. In the SPDR, this reverse transaction generates records with negative 
values. In Study I, Study II, and Study IV we excluded negative transactions 
and their corresponding positive transactions from the data set before 
estimating filled medication supplies. Thus, our assessment of refill adherence 
and persistence was considered reliable. However, the SPDR does not include 
medications distributed at hospitals; hence, we may have underestimated refill 
adherence and persistence in patients who were hospitalized during the study 
period. 
 
In Study I, Study II, and Study IV, we collected diagnosis codes for CVD from 
the National Patient Register. The National Patient Register is validated by the 
National Board of Health and Welfare and is estimated to have full coverage 
[105]. Patients’ PIN was estimated to be either missing or incorrect in 1.6% of 
all admissions between 1988 and 2016. Furthermore, an evaluation of patients’ 
diagnosis of acute myocardial infarction between 1987 and 1995 showed that 
diagnosis at discharge matched established diagnosis criteria in 86% of the 
cases [106]. Thus, the collection of CVD diagnosis from the National Patient 
Register is reliable. 
 
Coverage in the Cause of Death Register is considered complete because 
deaths are registered there regardless of whether any cause of death is reported 
[107]. However, there is some uncertainty regarding coverage of reported 
cause of death, which is missing in 1%–2% of the cases. Poorly specified 
information may require additional information, delaying data about cause of 
death. In Study I, Study II and Study IV, we collected date and cause of death 
from the Cause of Death Register. To ensure proper identification of CV 
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mortality, we considered both CVD as main or contributing cause of death, and 
diagnosis of CVD in the National Patient Register prior to death. 
5.2.3 Missing data 
This thesis is based on data from different registers with different degrees of 
missing information. Depending on the extent of missing data, the nature of 
missingness and the way one chooses to handle missing information often 
plays a major role in the outcome of statistical analyses. 
 
Missing completely at random refers to when there is no relationship between 
the missing information about a covariate and any values in the data set, 
missing or observed. In that case, running a statistical analysis based on 
observations with complete information about the covariates of interest (i.e., 
complete case analysis) may reduce the study population but will not introduce 
selection bias. If the missing information is not random (i.e., the missing value 
is related to the reason it is missing), complete case analysis may result in a 
small highly selective study population that does not represent the population 
of interest, thus introducing selection bias. However, excluding variables with 
missing information from the analysis could result in inaccurate conclusions 
due to unadjusted confounding. In this case, imputation of data may be 
suitable. 
 
Data collected from the SPDR, the National Patient Register, the Cause of 
Death Register, the Swedish Cancer Registry, and the LISA database contained 
little or no missing information. Because patients with T2DM usually visit 
their healthcare provider once a year and healthcare providers may not measure 
all characteristics each medical visit, variables in the NDR contains varying 
degrees of missing data. Although we cannot exclude the risk that data was 
missing not at random, we have no reason to believe that the healthcare 
providers would selectively exclude data. Because such data is most likely 
missing at random, we performed multiple imputation to replace missing data 
in Study II and Study IV. 
 
In Study I, we chose not to replace missing information. Instead, we analyzed 
the difference in refill adherence and persistence between primary and 
secondary prevention patients in three successive models. Moving from crude 
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to fully adjusted model (complete cases), we excluded 80% of the study 
population due to missing information. However, the difference in refill 
adherence and risk of discontinued treatment remained similar between the 
models, and the fully adjusted model included nearly 20,000 patients. Thus, 
the results of Study I are considered reliable. 
 
In Study II and Study IV, we replaced missing information by performing 
multiple imputations. We used sensitivity analyses to evaluate the impact of 
multiple imputations and obtained similar results for imputed data and 
complete case analyses. Thus, the risk of bias due to handling missing data was 
of little concern. 
 
In Study III, more than 50% of data had missing information about either LDL-
C, CVD, or lipid-lowering medication use. Since we considered these variables 
as exposures or outcomes, replacing missing information was not 
methodologically appropriate. However, the distribution of key variables 
defining the study population was similar between included and excluded data. 
Thus, exclusion of observations with missing information did not distort the 
composition of the study population. Nonetheless, we cannot exclude the 
possibility that data was missing not at random. 
5.2.4 Strengths and limitations 
The greatest strength of this thesis is the linkage of data between several 
national registers using the unique PIN, which allowed us to collect data from 
a large number of T2DM patients and extensively adjust for individualized risk 
factors. The NDR, which is one of the leading diabetes registers worldwide, 
collects data from both primary and specialized care clinics. This is a great 
strength because most T2DM patients receive treatment within primary care, 
which is not covered by the National Patient Register. Therefore, this thesis 
highly reflects clinical practice in Sweden. 
 
Another strength is our access to SPDR data about filled prescriptions, which 
allowed us to assess patients’ adherence based on the active behavior of 
patients rather than the prescriber. Using information on prescribed 
medications may overestimate patient adherence because not all patients fill 
their prescriptions. Although filled prescriptions do not equal ingestion of 
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medications, it takes us one step closer to the patients and their medication use. 
However, the SPDR does not include information about prescribed 
medications that were never filled. Hence, we could not estimate the extent of 
primary nonadherence (i.e., patients who never filled their initial prescription). 
 
The SPDR uniquely provided us with information about prescribed daily 
dosage, meaning we did not need to use a proxy. The algorithm we developed 
to convert the free-text variable that represented the daily dosage was validated 
in Study I, Study II, and Study IV, respectively. Hence, our assessment of filled 
supplies and measures of refill adherence is considered to highly reflect the 
intended medication use as prescribed. 
 
A major limitation of this thesis involves factors associated with prescription 
or use of lipid-lowering medications that were not considered in our studies. 
Because guidelines are intended for patients without contraindications, patients 
having any of these conditions should have been excluded or censored. 
Furthermore, we had no information about experienced adverse drug reactions, 
which would have been a legitimate cause for not prescribing lipid-lowering 
medications. Thus, we may have underestimated healthcare providers’ 
adherence to lipid-lowering prescription guidelines. 
 
In Study II and Study IV, we did not consider the substance or strength of 
medications when we analyzed risk of CV events and mortality. Although 
statins are by far the most widely used class of lipid-lowering medications in 
Sweden and worldwide, statins with greater potency to lower LDL-C can  
reduce the risk of a CV event, possibly explaining the difference in risk of a 
CV event. 
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6 CONCLUSIONS 
 
Our investigation of the association between risk of CV events and mortality 
in relation to patients’ refill adherence to lipid-lowering medications and 
healthcare providers’ adherence to lipid-lowering prescription guidelines 
among T2DM patients resulted in the following conclusions: 
 
Healthcare providers’ adherence to guidelines was higher among patients 
assigned to secondary prevention of CVD. Furthermore, the odds of receiving 
a prescription for lipid-lowering medications was higher among patients with 
risk factors of developing CVD (e.g., men, concurrent prescriptions for other 
cardioprotective medications, and smoking). 
 
Secondary prevention patients, those with concurrent use of other 
cardioprotective medications, and smokers showed higher refill adherence and 
longer persistence to lipid-lowering medications. Additionally, we observed 
lower refill adherence and higher risk of premature discontinuation among 
patients born outside of Sweden. 
 
Compared to high-adherent patients (i.e., refill adherence above 80%), the risk 
of a CV event was higher among low-adherent patients (i.e., refill adherence 
of 80% or less) and that risk gradually increased as refill adherence declined, 
independent of prevention type. Furthermore, risk of mortality was higher 
among low-adherent patients. However, we were unable to identify a clear 
trend among levels of refill adherence. 
 
With some exceptions, healthcare providers’ adherence to guidelines had little 
or no impact on T2DM patients’ adherence to refilling prescriptions for lipid-
lowering medications or patients’ risk of CV events and mortality. 
 
Out findings emphasize the value of individualized diabetes care among 
T2DM, and will be valuable to guideline and policy makers as well as 
healthcare providers and patients as they evaluate and improve the use of lipid-
lowering medications to ensure optimal, standardized and equal care among 
patients with T2DM. 
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7 CLINICAL IMPLICATIONS AND FUTURE PERSPECTIVE 
 
T2DM is a complex disease that requires an extensive treatment regimen in 
order to reduce the increased risk of morbidity and mortality. Our findings 
suggest that the extent to which patients take their lipid-lowering medications 
as prescribed had a greater impact on risk of CV events and mortality compared 
to the healthcare providers’ adherence to lipid-lowering prescription 
guidelines.  Additionally, we found differences in patients’ adherence and 
persistence to lipid-lowering medications associated with several patients’ 
characteristics (e.g., established CVD, country of birth, marital status, 
concurrent medications, smoking, etc.) To prevent therapy failure and risk of 
morbidity, healthcare providers should be aware and observant of differences 
in adherence and persistence. 
 
Although dyslipidemia is a strong risk factor for developing CVD, other risk 
factors also play a role. Hence, lipid-lowering medications are only part of the 
recommended treatment regimen in patients with T2DM. Patient who receive 
lipid-lowering medications often receive prescriptions for other 
cardioprotective medications as well. In fact, high adherence to lipid-lowering 
medications, glucose-lowering, and antihypertensives has separately been 
shown to associate with lower risk of CV events and mortality among T2DM 
patients [75]. Therefore, healthcare providers should consider patients’ 
adherence to all cardioprotective medications when analyzing the association 
between adherence and risk of CV events and mortality. From this, the 
question arises of whether any particular adherence pattern is more efficient in 
T2DM patients. For example, is high adherence to lipid-lowering medications 
more efficient in preventing CVD and mortality compared to the combined 
effect of low adherence to diabetes medications, lipid-lowering medications, 
antihypertensives, and anticoagulants? 
 
Dividing patients according to level of refill adherence tells little about the 
actual pattern of medication use. For example, patients with 50% refill 
adherence may take their medications less often than prescribed or they may 
be completely adherent during one half of a study period and then prematurely 
discontinue treatment. For those reasons, dividing patients according to their 
refill pattern over time (i.e., trajectories of medication adherence) may provide 
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a more accurate picture of medication use as an exposure. Previous studies 
have shown patient characteristics and the first filled prescriptions of lipid-
lowering medications to associate with predictions of future adherence 
trajectories [108]. Considering the comprehensive databases of filled 
prescriptions, healthcare-related data and socioeconomic variables, Sweden 
offers excellent opportunities for analyzing medication trajectories. These 
trajectories can be used by healthcare providers to estimate patients’ 
probability of developing patterns associated with increased risk of CV events 
and mortality, and thus identifying patients most likely to benefit from 
adherence interventions. 
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